Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

India's maritime build-out is accelerating, backed by naval expansion. Beyond shipyards, ancillary and service players are ...

AI is now a core part of business strategy, and leaders who understand how to use it can make faster decisions, drive ...

SALT LAKE CITY — Close to 60,000 structures across Utah are considered at "high risk" for being impacted by wildfires, putting some homeowners on the path to pay new fees, according to a new state map ...

Our review of Bay Area data shows that although San Francisco ranks high for social capital, there are significant variations ...

A review paper by scientists at Beijing Institute of Graphic Communication presented  a thorough review of the existing ...

As a cybersecurity engineer, she leads efforts to uncover and seal the different ways in which data can fall into the wrong ...

Days after its recent licensing deal with AI chip firm Groq, Nvidia is reportedly acquiring Israel AI firm AI21 Labs for a ...

VANCOUVER, BC, Dec. 31, 2025 /CNW/ - Goldsky Resources Corp (TSX-V: GSKR, FNSE: GSKR SDB, OTCQX: FNMCD, FRA: HEG0) ("Goldsky ...